ArticleCell biochemistry and biophysics2026
Bovine Colostrum-Derived Lactoferrin Nanoparticles as a Novel Platform for Improved Pulmonary Delivery of Osimertinib.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osimertinib (OSI), a third-generation EGFR tyrosine kinase inhibitor, has poor solubility and non-specific distribution, which limit its clinical effectiveness in NSCLC. To improve pulmonary delivery, OSI-loaded bovine lactoferrin nanoparticles (OSI@LFNPs) were developed and compared with OSI-loaded albumin nanoparticles (OSI@AlbNPs) using a desolvation method followed by glutaraldehyde crosslinking. These particles were characterized by DLS, zeta potential analysis, and FE-SEM. OSI@LFNPs showed a hydrodynamic size of 224.9 ± 18.1 nm, an acceptable polydispersity index (PDI) value, and a zeta potential of − 50.47 ± 12.23 mV, while OSI@AlbNPs measured 407.0 ± 125.1 nm with a nearly neutral surface charge (0 ± 0 mV). FE-SEM images confirmed the presence of well-formed protein-based nanoparticles, with lactoferrin displaying smoother surfaces compared to the rougher, clefted structure of albumin. Encapsulation efficiency and loading capacity were 49.03 ± 2.60% and 54.54 ± 2.89% for LFNPs, versus 38.99 ± 1.33% and 43.38 ± 1.48% for AlbNPs, respectively, with low polydispersity indicating uniform dispersions. Release studies revealed temperature- and pH-responsive behavior; kinetic modeling showed a first-order release for LFNPs (R²=0.9929) and Higuchi diffusion for AlbNPs (R²=0.9803). In vivo biodistribution in rats showed significantly higher lung accumulation with LFNPs (33.64 ± 1.26% of the injected dose) compared to AlbNPs (15.27 ± 1.45%) and free OSI (18.47 ± 2.83%) (p < 0.001), along with reduced renal uptake relative to AlbNPs. Overall, LFNPs offer higher drug loading, favorable colloidal properties, controlled release, and superior lung targeting, supporting their potential as a biocompatible carrier to enhance OSI bioavailability and therapeutic efficacy in NSCLC.
Indexed as
Identifiers
41134471What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.